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Introduction: The Manchester Adult CF Centre (MACFC) provides care for adults
with cystic ﬁbrosis (CF) who live in the North West of England. The Manchester
Adult CF Centre receives new patient referrals from two large paediatric CF centres
in the region, a number of smaller paediatric CF centres, and occasionally other
CF centres and non-CF units. As part of our ongoing microbiological surveillance
program for P. aeruginosa cross-infection, we perform strain typing of isolates from
all new patients with chronic P. aeruginosa infection.
Methods: P. aeruginosa isolates from sputum of patients with chronic infection at
their ﬁrst visit to the MACFC were sent to a national CF microbiology reference
laboratory for strain typing by pulsed-ﬁeld gel electrophoresis.
Results: 55 patients referred to MACFC between 2005–2007 were known to have
chronic P. aeruginosa infection. 18 (32.7%) patients were found to be infected with
a transmissible strain (13× LES, 3× MA, 2×other local strain). Of the referrals, 31
were from the main regional paediatric centres, of whom 12 (38.7%) were found be
infected by transmissible strains (8× LES, 2× MA, 2× other local strain). One of
3 patients transferred from other adult CF centres was infected with a transmissible
strain (LES strain). Five of 17 (29.4%) of patients from smaller DGH paediatric
units were infected with a transmissible strain (4× LES, 1× MA strain). Neither
the 3 patients referred from non-CF adult units or another patient referred form
a large paediatric CF centre outside our region were infected with a transmissible
P. aeruginosa strain.
Conclusions: All patients with CF should have strain typing of P. aeruginosa and
strain typing results should be provided at referral to another CF centre.
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Background: Transmission of some strains of Psa within and across CF centres
is now recognised and the clinical signiﬁcance is yet to be determined. This study
reviews a change in prevalence of clonal Psa at 2 CF centres between 2002 & 2005.
Method: Sputum samples were collected from patients with chronic Psa infection
at the Royal Children’s Hospital (RCH) & The Prince Charles Hospital CF Centres
(TPCH) in 2002 & 2005. PCR was performed at a research laboratory.
Results: Sputum was collected from 124 TPCH patients in 2002 and 161 patients
in 2005. Sputum was collected from 87 RCH patients in 2002 and 70 patients
in 2005. 3 major clonal strains were identiﬁed ie. P2, P42 & P1. Other strains
were classiﬁed as minor clonal &/or unique strains. The TPCH prevalence of P2
was 38.7% in 2002, increasing to 54.0% in 2005 and 48.3% to 48.6% at RCH.
The prevalence of P42 has increased from 6.5% to 10.6% at TPCH and 13.8% to
17.1% at RCH. The prevalence of P1 has increased from 6.5% to 10.6% at TPCH
and 4.6% to 5.7% at RCH. There were 44 new P2 infections at TPCH between
2002 and 2005.21 patients acquired new clonal strain infection within the TPCH
centre.23 known cases were transferred into TPCH.
Conclusions: There has been an increase in the prevalence of all major clonal
strains. Complete cohort segregation is under consideration. Study of the long-term
clinical impact of clonal Psa strain infection is underway.
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Background: The impact of clonal Psa upon LT outcomes in CF is uncertain.
Method: CF patients with chronic Psa infection who have undergone LT at 2 large
adult CF centres (2000−06) were identiﬁed retrospectively.
Results: TPCH Centre had 29 CF patients (6 clonal, 1 minor clonal, 14 unique,
6 unknown genotype, 2 without Psa) transplanted 2000−06. MACFC had 11 CF
patients (7 unique Psa, 4 clonal Psa) transplanted. Median FEV1 6 months pre-
transplant was 32% (13−56%) predicted for clonal Psa and 26% (15−41%) predicted
for unique Psa. Median BMI 6 months pre-transplant was not different between the
groups. Median intravenous (iv) antibiotic days over 12 months pre-transplant was
119 (37–297) for clonal Psa and 87 (24–331) for unique Psa. Median stay in the
ICU post-operatively was 4 days (2−85) for clonal Psa and 3 days (1−34) for unique
Psa. The median FEV1 6 months post-transplant was 72% predicted (32–105%) for
clonal Psa and 78% predicted (44–129%) for unique Psa. Median BMI 6 months
post-transplant was not different between the groups. Median iv antibiotic days at
12 months post-transplant was 19 (0–116) for clonal Psa and 22 (4−69) for unique
Psa. 4 of 5 deaths post-transplant were in the clonal group.
Conclusions: No difference was noted in ICU stay or iv antibiotic use post-
transplant. The highest mortality post-transplant was seen with clonal strains.
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Introduction: Transmissible Pseudomonas aeruginosa strains are becoming in-
creasingly common in CF, and although they have been shown to confer a worse
prognosis, their effect on the cost of CF care remains unknown.
Method: To look at this further, we compared the need for IV therapy over 12
months (2006) in a group of 127 CF patients infected by the commonest UK strain
(the Liverpool Epidemic Strain, LES) with 70 patients infected by unique strains
attending our large adult CF unit. The 2 groups were matched for age (LES: mean
24 years [range 17 to 51] versus 25 [17 to 49]) and lung function (mean FEV1%:
68 [20 to 111] v 75 [22 to 128]) (both P=NS).
Results:More patients infected with LES required IV treatment (89 v 32, c2 = 11.3,
P< 0.001), more of this was given in hospital (81 v 26, c2 = 12.9, P< 0.001), for a
longer period each time (mean 14.5 days v 12.0, P< 0.05). Although LES patients
consumed more bed days than the remainder (22.8/patient/year v 7.7, P< 0.001), a
similar proportion required outpatient IV treatment (LES: 55 episodes in 34 patients
v 33/16, P =NS), with a similar requirement for treatment days (6.2/patient/year v
5.6, p =NS). A wide range of different antipseudomonal antibiotics were used for
each group both as inpatients and outpatients.
Conclusions: This study shows that patients infected with the commonest UK
transmissible strain, LES, require more IV treatment than other CF patients, and
more of this is given in hospital. Transmissible Pseudomonas aeruginosa strains
increase the treatment burden for CF patients, emphasising the need for effective
segregation strategies in CF units to prevent cross infection with such organisms.
